KTOS vs RCAT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. KTOS and RCAT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined KTOS and RCAT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Kratos Defense & Security Solutions (KTOS) is a defense technology company that specializes in affordable, high-performance systems the U.S. military wants to buy in volume. Its two segments are Unmanned Systems, home to the XQ-58 Valkyrie collaborative combat aircraft and other tactical drones and target drones, and Kratos Government Solutions, which spans hypersonic systems (Erinyes, Dark Fury), solid rocket motors, turbine and jet engines, microwave electronics, C5ISR, space, training and cyber. The common thread is being the low-cost, fast-to-field alternative to legacy prime contractors, which lines up with Pentagon demand for attritable, mass-producible hardware.

Full KTOS guide

Red Cat Holdings makes small unmanned aerial systems for military and public safety customers, principally through its Teal Drones subsidiary, which produces short-range reconnaissance drones for defence programmes. On October 12, 2026, at the AUSA 2026 conference, the company launched Red Cat Aerial, a unit that brings its unmanned aircraft portfolio under one brand, and unveiled TRICHON, a long-endurance vertical take-off intelligence, surveillance and reconnaissance (ISR) drone, alongside a new hand-launched system.

Full RCAT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• KTOS drivers: Valkyrie and collaborative combat aircraft; Hypersonics, rockets and engines.
• RCAT drivers: US-manufactured drones for defence procurement; Short-range reconnaissance programme exposure.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Valuation remains the dominant risk even after the 2026 sell-off: at about 238x trailing and 36x forward earnings, the stock still prices in years of sustained growth, and the roughly 49% year-to-date decline shows how sharply it can derate when sentiment on defense and drone names turns. For RCAT, red Cat is a small, loss-making company whose value depends heavily on defence programme awards that may be delayed, reduced or lost.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick KTOS if you believe its drivers more; RCAT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the KTOS and RCAT guides.

KTOS. As of October 2026, Kratos is growing revenue about 30 percent a year while earning only about 2 cents of net income per dollar of sales, so the trailing P/E is in the hundreds and price-to-sales is about 5 times, down from roughly 7 times in the spring after the stock fell about 49 percent. The forward P/E near 36x assumes EPS rises to about $1.11 in 2027. The mean analyst target of about $98 sits far above the current price, while new coverage from Macquarie in October came in at $70.

RCAT. Red Cat's valuation rests on future programme awards rather than on current earnings, which makes it highly sensitive to procurement news. At roughly ~10x trailing sales after a ~48% fall in 2026, the price still assumes revenue roughly doubles from the trailing ~$71.5 million to the ~$151 million analysts expect for 2026. The next report, expected around November 5, 2026, will show whether the September quarter reached the ~$41 million consensus. Verify the current cash position, share count and contract status.

Headline figures (approximate, October 2026): KTOS shows revenue (q2 2026) ~$459M, up ~30% YoY, revenue (ttm) ~$1.52B, 2026 revenue (analyst consensus) ~$1.79B, net income (ttm) ~$31M (~2% margin); RCAT shows revenue (ttm) ~$71.5 million to June 30, 2026; Q2 2026 ~$20.2 million, up roughly ~527% year over year, margins (ttm) Gross ~10%, operating ~-191%, net loss ~$97.5 million TTM; Q2 2026 ~$35.3 million, EPS ~-$0.23 versus ~-$0.17 expected, cash and debt Cash ~$325.6 million, debt ~$14.9 million; TTM operating cash outflow ~$139 million.

KTOS and RCAT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined KTOS and RCAT exposure against your real portfolio. It is not an investment adviser.